• Donate
  • Contact
Canadian Association of Pompe
  • Home
  • About Us
    • Portraits of Pompe
    • Our Partners
    • Newsletter
  • About Pompe
    • Talk Pompe
    • Webinars
  • Blog
  • Links
  • Connections
Select Page
Genzyme Study of Myozyme® for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints

Genzyme Study of Myozyme® for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints

by CAP | Dec 13, 2007 | Press Releases

Recent Posts

  • Pompe Empowerment Program (PEP) 2022
  • Avalglucosidase Alfa (Nexviazyme™) approved by Health Canada
  • Elizabeth
  • FDA approves Nexviazyme® (avalglucosidase alfa-ngpt)
  • Emerging From the Pandemic: Pompe Perspectives
  • Terms
  • Privacy

Copyright © 2006 - 2022 Canadian Association of Pompe